• KPTI

Earnings call: Karyopharm Therapeutics reports on clinical and financial progress

Karyopharm Therapeutics updates on Q3 2024 results, highlighting Phase 3 trials, financial performance, and ongoing opportunities in myelofibrosis and endometrial cancer treatment.